Attributes | Values |
---|
rdf:type
| |
Description
| - Anti-idiotype monoclonal antibody targeted N-(2-hydroxypropyl)methacrylamide copolymer bound doxorubicin is able to completely cure mice with BCL-1 B-cell leukemia. During the treatment the immune system is activated and effective long-term anti-tumor immunity is established. This immune reaction requires CD4+ and CD8+ cells.
- Anti-idiotype monoclonal antibody targeted N-(2-hydroxypropyl)methacrylamide copolymer bound doxorubicin is able to completely cure mice with BCL-1 B-cell leukemia. During the treatment the immune system is activated and effective long-term anti-tumor immunity is established. This immune reaction requires CD4+ and CD8+ cells. (en)
- Antiidiotypovou protilátkou směrovaný polymerní konjugát bázi N-(2-hydroxypropyl)metakrylamidu nesoucí cytostatikum doxorubicn, je schopen na rozdíl od volného léčiva zcela vyléčit myši s BCL-1 leukémií. Během léčby je aktivován imunitní systém a je navozena dlouhodobá protinádorová imunita, která je závislá na přítomnosti CD4+ a CD8+ buněk v organismu myší. (cs)
|
Title
| - T cell subsets play a vital role in generation of anti-tumor immunity induced in mice treated with antibody-targered HPMA copolymers containing doxorubicin
- T buňky mají zásadní úlohu při vytvoření protinádorové imunity u myší léčených protilátkou směrovanými konjugáty doxorubicinu a HPMA (cs)
- T cell subsets play a vital role in generation of anti-tumor immunity induced in mice treated with antibody-targered HPMA copolymers containing doxorubicin (en)
|
skos:prefLabel
| - T cell subsets play a vital role in generation of anti-tumor immunity induced in mice treated with antibody-targered HPMA copolymers containing doxorubicin
- T buňky mají zásadní úlohu při vytvoření protinádorové imunity u myší léčených protilátkou směrovanými konjugáty doxorubicinu a HPMA (cs)
- T cell subsets play a vital role in generation of anti-tumor immunity induced in mice treated with antibody-targered HPMA copolymers containing doxorubicin (en)
|
skos:notation
| - RIV/61388971:_____/04:00000398!RIV/2005/AV0/A53005/N
|
http://linked.open.../vavai/riv/strany
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - P(GD310/03/H147), P(IAA4050201), P(IBS5020101), Z(AV0Z5020903)
|
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/61388971:_____/04:00000398
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - hpma; anti-tumor immunity (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...v/mistoKonaniAkce
| |
http://linked.open...i/riv/mistoVydani
| |
http://linked.open...i/riv/nazevZdroje
| - International Conference on Tumor Microenvironment: Progression, Therapy and Prevention /3./
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...iv/tvurceVysledku
| - Etrych, Tomáš
- Kovář, Marek
- Strohalm, Jiří
- Ulbrich, Karel
- Říhová, Blanka
- Plocová, Daniela
- Mrkvan, Tomáš
|
http://linked.open...vavai/riv/typAkce
| |
http://linked.open.../riv/zahajeniAkce
| |
http://linked.open...n/vavai/riv/zamer
| |
number of pages
| |
http://purl.org/ne...btex#hasPublisher
| |